Page 24 - தலை ஆஃப் பெருநிறுவன வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates March 9, 2021 GMT BEDFORD, Mass. (BUSINESS WIRE) Mar 9, 2021 Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2020 and provided business updates. “During the last year, the power and potential of RNA medicines became clear to the world. Simultaneously, the Stoke team advanced our efforts to discover and develop RNA-based medicines that aim to address the underlying cause of severe genetic diseases by selectively boosting protein production,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Our Phase 1/2a MONARCH study in children and adolescents with Dravet

United statesUnited kingdomEdwardm kayeAmerican epilepsy societyAugmentation of nuclear gene outputStoke therapeutics incExchange commissionAugmentation of nuclear gene output is stokeHead of corporate affairsChief executive officerTargeted augmentationNuclear gene outputClinical studyAutosomal dominant optic atrophyPrivate securities litigation reform actRisk factors